Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. More is better: Combination therapies for myelodysplastic syndromes

    ... FDA-approved medications for MDS; lenalidomide , azacitidine , and decitabine . The role of these agents is to ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    ... efficacy of disease-modifying therapies, such as azacitidine or lenalidomide . The recombinant human ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... for its treatment: lenalidomide , 5- azacitidine , and decitabine . These therapies can be effective in ... and reduction in bone marrow blasts . 5-azacitidine has also been shown to improve overall survival. However, there ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up

    ... Hypomethylating agents (HMA), such as 5- azacitidine or decitabine , are currently used to treat patients ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Recent developments in myelodysplastic syndromes

    ... in the United States (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Update on the pharmacotherapy for myelodysplastic syndromes

    ... of these complex malignancies: lenalidomide , azacitidine and decitabine . AREAS COVERED: This review ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes

    ... appropriate for all patients. Two demethylating agents, azacitidine and decitabine , are approved for treatment of MDS, ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. How we treat higher-risk myelodysplastic syndromes

    ... Standard therapies include the hypomethylating agents azacitidine and decitabine , which should be administered for a ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

    ... At diagnosis, 86% of MDS patients are ≥60 years. Azacitidine , the only drug that prolongs life in high-risk (HR)-MDS ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Current therapy of myelodysplastic syndromes.

    ... (MDS). On the therapeutic front, the approval of azacitidine , decitabine , and lenalidomide in the last ...

    Research Article last updated 07/20/2018 - 5:15pm.